News
H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...
Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...
Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.
Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic ...
CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
2d
Zacks Investment Research on MSNWhy Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 7.7% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results